US Stock Insider Trading | Tyra Biosciences disclosed two insider trading transactions on March 17

K-LinePoet · 2026-04-01T08:18:36+00:00

Tyra Biosciences disclosed insider trading activities on March 17, 2026, including director Harris Todd and executive Fuhrman Alan purchasing shares on March 13. Meanwhile, executive Bensen Daniel has recently sold shares multiple times. The company focuses on precision oncology, dedicated to improving treatment outcomes for cancer patients.

K-LinePoet

2026-04-01 08:18:36

Abstract generation in progress

On March 17, 2026, Tyra Biosciences (TYRA) disclosed two insider trading transactions by company insiders. On March 13, 2026, director Harris Todd purchased 1,463 shares.

[Recent Insider Trading]

Disclosure date	Position	Name	Transaction date	Buy/Sell	Quantity	Price per share/US$	Total amount/US$
March 17, 2026	Director	Harris Todd	March 13, 2026	Buy	1463	9.13	$14,300
March 17, 2026	Executive	Fuhrman Alan	March 13, 2026	Buy	1376	9.13	$12,560
February 13, 2026	Executive	Bensen Daniel	February 12, 2026	Sell	2128	31.50	$67,020
February 13, 2026	Executive	Bensen Daniel	February 12, 2026	Sell	5872	33.37	$195,900
January 20, 2026	Executive	Bensen Daniel	January 12, 2026	Sell	6983	28.44	$198,600
January 20, 2026	Executive	Bensen Daniel	January 12, 2026	Sell	1017	29.08	$29,600
December 19, 2025	Director	MORE ROBERT J	December 19, 2025	Sell	10,000	25.00	$250,000
December 16, 2025	Executive	Bensen Daniel	December 12, 2025	Sell	8,000	22.64	$181,000
November 25, 2025	Director	MORE ROBERT J	November 21, 2025	Sell	246,900	20.25	$5,000,000
November 19, 2025	Executive	Bensen Daniel	November 18, 2025	Sell	75,600	16.07	$1,213,560

[Company Profile]

Tyra Biosciences, Inc. was incorporated in the state of Delaware on August 2, 2018. The company is a precision oncology company focused on developing proprietary therapies to overcome tumor drug resistance and improve treatment outcomes for cancer patients. The company is using its proprietary SNAP platform, which has been optimized to rapidly and precisely improve structural design through iterative molecular SNAPshots, generating the next-generation candidate products specifically designed to address acquired resistance and provide alternative treatment options.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes